The researchers noticed a high production of antibodies in the volunteers 14 days after the vaccine was administered. It was developed following the same technique than Pfizer’s.
Those individuals had received two shots of inactivated vaccines such as Sinopharm and Sinovac.
According to Global Times daily, no thrombosis cases or other major adverse effects were detected during the clinical trials, and the conclusions indicate that the immune response will last longer.
Research started in Jiangsu province in June, and the plan was to recruit 300 healthy volunteers, aged from 18 to 59.
Some experts uphold the idea of using the same vaccine in the additional shot, while others believe that using a different type is more effective and rule out the possibility of many adverse effects.
The Chinese government is considering administering a booster shot to elderly people, health workers and other vulnerable sectors, due to the spread of more dangerous variants of the SARS-CoV-2 coronavirus, like the Delta one.